A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Clinical trial NCT04927247 · TERMINATED

Trial details

NCT number: NCT04927247
Sponsor: Pfizer
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Sickle Cell Disease Vaso-occlusive Crisis Vaso-occlusive Pain Episode in Sickle Cell Disease

Start date: 2021-12-09
Primary completion: 2023-11-24
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.